The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
The user experienced hair loss despite using Fin and Min for 12 years and switched to Dutasteride, RU58841, and Keto scalp serum, but shedding and itch persist. They are considering increasing Dutasteride to 2.5mg and questioning the necessity of a scalp biopsy, with mixed opinions on its usefulness.
The user has been using a topical treatment combining finasteride, minoxidil, and caffeine for 9 months without noticing any changes and is inquiring about blood tests to check for finasteride resistance. They had their DHT levels checked, which were 54 ng/dl, and are planning to share progress pictures soon.
The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.
A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.
The post and conversation are about the long-term side effects of using Dutasteride and Finasteride for hair loss, including issues like raised liver enzymes, high cholesterol, and loss of libido. The user advises regular blood work and careful monitoring for those using these treatments.
The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.
A user discusses a company, Roots by Genetic Arts, that offers a genetic test for hair loss to create personalized treatments, and is curious about its legitimacy and the science behind it. The company tests 16 genes related to hair loss and compounds a topical treatment based on the results.
The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.
The user is concerned about hair loss despite using oral finasteride, oral minoxidil, and topical minoxidil. They are seeking advice on additional blood tests to identify potential causes.
The user is on Finasteride for hair loss, taking 0.5mg daily, and plans to reduce the dose to 0.25mg while making lifestyle changes to lower prolactin, SHGB, and cortisol. They will retest in 90 days to assess progress and are open to advice.
A 23-year-old with high estrogen levels is considering starting finasteride for hair loss and plans to use a low dose topical treatment while also seeking to lower estrogen levels. They will consult an endocrinologist for further guidance.
A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.
High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.
A user is considering starting finasteride for hair loss and shares their hormone levels, with others suggesting checking SHBG and discussing potential side effects. Some recommend starting with 0.5 mg finasteride, while others suggest considering dutasteride.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.
Vitamin D tests like D2, D3, and 25-hydroxyvitamin D are discussed before starting hair treatment. Vitamin D can be obtained from food, but overdose has side effects.
The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.
The user shared their experience with hair loss treatments, including oral and topical Finasteride and Minoxidil, and detailed various blood test results to track hormonal changes. They noted that while DHT levels initially decreased with topical Finasteride, they later increased, but they observed positive results in hair growth.
A user on finasteride for 8 months shared bloodwork results showing increased testosterone and estradiol levels, with concerns about high LH. Responses advised monitoring for symptoms but noted levels are within reference ranges.
The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.
The user is considering blood tests to understand their receding hairline and is exploring brewer's yeast for its biotin content. They have been using topical Minoxidil, biotin, collagen, and microneedling, but are avoiding oral Finasteride and Dutasteride.
The user is considering reducing RU58841 dosage from 100mg to 17.5mg for long-term safety due to brain fog issues from finasteride. They apply RU58841 only to the front of the scalp where thinning occurs.